E2F1 and cancer: The induction of E2F1 requires PI3Kδ and inhibitors of PI3Kδ (Idelalisib) have been tested in the clinic for non-EBV related cancers and it might be worth considering using PI3Kδ inhibitors against EBV-carrying cancers (51).